Literature DB >> 3863705

Differential cellular retention of vincristine and vinblastine by cultured human promyelocytic leukemia HL-60/Cl cells: the basis of differential toxicity.

P J Ferguson, C E Cass.   

Abstract

Differential toxicity of vincristine and vinblastine against cells of a cloned subline of human promyelocytic leukemia (HL-60/Cl) was dependent on exposure conditions. During continuous exposures of 48 h, vincristine and vinblastine were equitoxic with drug concentrations that inhibited proliferation rates by 50% of 7.6 and 8.1 nM, respectively. When cells were subjected to 4-h exposures and transferred to drug-free medium, the drug concentration of vinblastine that inhibited proliferation rates by 50% (1.1 microM) was significantly greater than that of vincristine (41 nM). Analysis by flow cytometry of the effects of equitoxic drug exposures on cell-cycle progression suggested that vincristine and vinblastine acted by the same mechanism (G2-M phase inhibition). [3H]Vincristine and [3H]vinblastine were bound to serum proteins in growth medium to the same extent (25%) over a wide range of concentrations, and the amounts of "free" extracellular drug did not decrease during prolonged exposures. Analysis by high-performance liquid chromatography of extracts of cultures incubated with growth-inhibitory concentrations of [3H]vincristine or [3H]vinblastine indicated little, if any, metabolism of either drug by cells or culture fluids; after 24 h, 85-95% of radioactivity was recovered from cells or growth medium as unchanged vincristine or vinblastine. At concentrations from 6 nM to 6 microM, vinblastine entered cells rapidly, reaching maximum levels within 0.5-2 h, and the relationship between maximal cell-associated drug and extracellular free vinblastine was linear. Although uptake of vincristine was slower than that of vinblastine, the cellular content of vincristine reached that of vinblastine during prolonged (12-24 h) exposures, and the amounts of cell-associated drug, relative to extracellular drug concentrations, indicated considerable "concentrative" accumulation (intra: extracellular ratios, greater than 100). When drug exposures were ended by transfer of cells to drug-free medium, vinblastine was released from cells more rapidly and to a greater extent than vincristine, independent of whether exposures were 4 or 24 h. Rates of uptake and release of vinblastine (50 nM) were unaffected by depletion of cellular adenosine triphosphate, suggesting that rapid release was not mediated by an energy-dependent efflux system.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3863705

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Clinical pharmacokinetics of vinorelbine.

Authors:  D Levêque; F Jehl
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

2.  Role of the OATP Transporter Family and a Benzbromarone-SensitiveEfflux Transporter in the Hepatocellular Disposition of Vincristine.

Authors:  Johan Nicolaï; Louise Thevelin; Qi Bing; Bruno Stieger; Hugues Chanteux; Patrick Augustijns; Pieter Annaert
Journal:  Pharm Res       Date:  2017-08-21       Impact factor: 4.200

3.  Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative.

Authors:  A Pierré; V Pérez; S Léonce; J A Boutin; D Saint-Dizier; P Hautefaye; G Lavielle; G Atassi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Proteasomes are a target of the anti-tumour drug vinblastine.

Authors:  M Piccinini; O Tazartes; C Mezzatesta; E Ricotti; S Bedino; F Grosso; U Dianzani; P A Tovo; M Mostert; A Musso; M T Rinaudo
Journal:  Biochem J       Date:  2001-06-15       Impact factor: 3.857

Review 5.  Preclinical and clinical pharmacology of vinca alkaloids.

Authors:  X J Zhou; R Rahmani
Journal:  Drugs       Date:  1992       Impact factor: 9.546

6.  Interactions of vinblastine and vincristine with methotrexate transport in isolated rat hepatocytes.

Authors:  E Smeland; R M Bremnes; A Bessesen; R Jaeger; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Verapamil sensitizes normal and neoplastic rodent intestinal tissues to the stathmokinetic effect of vincristine in vivo.

Authors:  P Ince; D R Appleton; K J Finney; M Moorghen; J P Sunter; A J Watson
Journal:  Br J Cancer       Date:  1988-04       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.